Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC


At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

CancerNetwork® sat down with Chung-Han Lee, MD, PhD, from Memorial Sloan Kettering Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about potential implications of using frontline pembrolizumab (Keytruda) and lenvatinib (Lenvima) for non–clear cell renal cell carcinoma (RCC), which will be examined in the phase 2 KEYNOTE-B61 trial (NCT04704219) that is currently recruiting patients. He discussed how patients respond to immune check point inhibitors and what benefits they could see from using this specific combination.


What we already know about the non­–clear cell [RCC] space is that pembrolizumab is a very active agent. However, not everyone responds [with] the addition of an a tyrosine kinase inhibitor to an immune checkpoint inhibitor. We do hope to see continued responses. I think one of the key questions that we hope to answer eventually, is whether or not they’re distinct subpopulations that particularly benefit from this type of combination, and also whether or not these 2 compounds interact with each other in such a way that provides synergism.


Chung-Han L, Chenxiag L, Rodolfo PF, et al. Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol. 39;2021(suppl 15):TPS4595. doi:10.1200/JCO.2021.39.15_suppl.TPS4595

Related Videos
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content